Breaking News Instant updates and real-time market news.

APHA

Aphria

$5.56

-0.27 (-4.63%)

, HAIN

Hain Celestial

$15.61

-0.17 (-1.08%)

17:39
12/27/18
12/27
17:39
12/27/18
17:39

Aphria appoints Hain Celestial's Irwin Simon as independent Chair

Aphria (APHA) announced that it has appointed Irwin D. Simon as independent Chair of Aphria's Board of Directors, effective immediately. Vic Neufeld, the current Chair, will remain Aphria's CEO and a director on Aphria's board. The appointment of an independent Chair advances the Company's governance best practices, with the Board now comprised of ten directors with a majority, or six directors, that are independent. Aphria remains committed to strong corporate governance and promoting a culture of integrity and ethical behaviour throughout the organization. Simon founded The Hain Celestial Group (HAIN) a leading organic and natural products company, in 1993. As Founder, President, Chief Executive Officer and Chairman, Mr. Simon lead Hain Celestial for 25 years, growing the business to approximately US$3B in net sales including operations in North America, Europe, Asia and the Middle East.

APHA

Aphria

$5.56

-0.27 (-4.63%)

HAIN

Hain Celestial

$15.61

-0.17 (-1.08%)

  • 11

    Jan

APHA Aphria
$5.56

-0.27 (-4.63%)

HAIN Hain Celestial
$15.61

-0.17 (-1.08%)

11/12/18
LOOP
11/12/18
NO CHANGE
Target $24
LOOP
Hold
Hain Celestial price target lowered to $24 from $29 at Loop Capital
Loop Capital analyst Andrew Wolf lowered his price target on Hain Celestial to $24 after its Q1 results, saying the 36% decline in EBITDA amid "increased trade spending, higher costs, and supply disruptions was bigger than he expected". The analyst notes that the company's new CEO should start to "focus on marketing spending on the best opportunities" within its brand portfolio, but expects this to be a "multi-year process". Wolf adds that although consumption trends have showed signs of improving, he sees Hain Celestial's near-term risk-reward as "balanced", keeping his Hold rating.
12/17/18
MAXM
12/17/18
NO CHANGE
Target $36
MAXM
Buy
New Hain Celestial CEO the right man to turn around company, says Maxim
Maxim analyst Anthony Vendetti reiterated a Buy rating and $36 price target on Hain Celestial after attending a luncheon with new CEO Mark Schiller. In a research note to investors, Vendetti says he believes Schiller is the "right man" to turn around the company and is convinced that the board is aligned with the new CEO. Looking ahead, the analyst expects Hain to focus on streamlining its business to reduce complexity and improve efficiency and believes the company must first sell Hain Pure Protein and streamline the rest of its business.
12/17/18
BMOC
12/17/18
NO CHANGE
Target $23
BMOC
Market Perform
Hain Celestial hinted guidance, consensus may be too high, says BMO Capital
BMO Capital analyst Amit Sharma said a recent sell-side lunch meeting with Hain Celestial's newly appointed CEO provided a "large serving" of what the problems are but not enough on either the potential solutions or how long a turnaround could take. Meanwhile, management hinted current FY19 EBITDA guidance, and even the current consensus estimate, "may be too high," according to Sharma, who lowered his price target on Hain shares to $23 from $25 ahead of the company's investor day. Sharma keeps a Market Perform rating on Hain.
12/19/18
LOOP
12/19/18
NO CHANGE
Target $18
LOOP
Hold
Hain Celestial price target lowered to $18 from $24 at Loop Capital
Loop Capital analyst Andrew Wolf lowered his price target on Hain Celestial to $18 and kept his Hold rating following its recent event to introduce the new CEO, Mark Schiller. The analyst notes that Schiller brings an "impressive" track record of a turnaround in food companies through a bottom up approach that "builds value across the brand portfolio". However, Wolf adds that the event's discussion also illuminated the extend of the "unknown at Hain", especially in identifying which brands will be the value creators for the enterprise. While Wolf has a positive impression regarding the fit of the new CEO for the needs of the company, he remains concerned about its lack of visibility.

TODAY'S FREE FLY STORIES

MS

Morgan Stanley

$42.16

-0.24 (-0.57%)

07:21
01/24/19
01/24
07:21
01/24/19
07:21
Hot Stocks
Morgan Stanley CEO: Shutdown could have 'extremely damaging' impact »

Gorman is speaking to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PAH

Platform Specialty Products

$10.90

-0.15 (-1.36%)

07:19
01/24/19
01/24
07:19
01/24/19
07:19
Hot Stocks
Platform Specialty Products receives regulatory approval for Arysta sale »

Platform Specialty…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MB

Mindbody

$36.41

-0.19 (-0.52%)

07:19
01/24/19
01/24
07:19
01/24/19
07:19
Downgrade
Mindbody rating change  »

JMP downgrades Mindbody…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PANW

Palo Alto Networks

$205.77

2.77 (1.36%)

07:18
01/24/19
01/24
07:18
01/24/19
07:18
Upgrade
Palo Alto Networks rating change  »

Palo Alto Networks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 25

    Feb

PG

Procter & Gamble

$94.87

4.37 (4.83%)

07:18
01/24/19
01/24
07:18
01/24/19
07:18
Recommendations
Procter & Gamble analyst commentary  »

Procter & Gamble…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Feb

  • 03

    Mar

NMCI

Navios Maritime Containers

$3.03

(0.00%)

07:17
01/24/19
01/24
07:17
01/24/19
07:17
Hot Stocks
Navios Maritime Containers exercises option to acquire containership for $52.5M »

Navios Maritime…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAPR

Capricor Therapeutics

$0.58

-0.0751 (-11.46%)

07:17
01/24/19
01/24
07:17
01/24/19
07:17
Hot Stocks
Capricor Therapeutics announces HOPE-Duchenne trial results published »

Neurology, an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TXN

Texas Instruments

$95.49

-1.05 (-1.09%)

07:17
01/24/19
01/24
07:17
01/24/19
07:17
Recommendations
Texas Instruments analyst commentary  »

Texas Instruments price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

NESRF

Northern Star Resources

$0.00

(0.00%)

07:16
01/24/19
01/24
07:16
01/24/19
07:16
Downgrade
Northern Star Resources rating change  »

Northern Star Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:15
01/24/19
01/24
07:15
01/24/19
07:15
General news
FX Update: The dollar has posted advances »

FX Update: The dollar has…

EEX

Emerald Expositions Events

, RELX

RELX

$21.78

-0.03 (-0.14%)

07:14
01/24/19
01/24
07:14
01/24/19
07:14
Recommendations
Emerald Expositions Events, RELX analyst commentary  »

Emerald Expositions a…

EEX

Emerald Expositions Events

RELX

RELX

$21.78

-0.03 (-0.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PG

Procter & Gamble

$94.87

4.37 (4.83%)

, EL

Estee Lauder

$126.94

1.19 (0.95%)

07:14
01/24/19
01/24
07:14
01/24/19
07:14
Recommendations
Procter & Gamble, Estee Lauder, Church & Dwight analyst commentary  »

P&G report has…

PG

Procter & Gamble

$94.87

4.37 (4.83%)

EL

Estee Lauder

$126.94

1.19 (0.95%)

CHD

Church & Dwight

$65.45

-0.7 (-1.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

  • 05

    Feb

  • 18

    Feb

  • 03

    Mar

  • 28

    May

USAP

Universal Stainless & Alloy

$14.62

-0.515 (-3.40%)

07:14
01/24/19
01/24
07:14
01/24/19
07:14
Hot Stocks
Universal Stainless & Alloy increases low alloy VAR bar base price 5%-10% »

Universal Stainless &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLNX

Xilinx

$89.55

-0.89 (-0.98%)

07:12
01/24/19
01/24
07:12
01/24/19
07:12
Recommendations
Xilinx analyst commentary  »

Xilinx price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

CNOB

ConnectOne Bancorp

$20.08

-0.19 (-0.94%)

07:11
01/24/19
01/24
07:11
01/24/19
07:11
Earnings
ConnectOne Bancorp reports Q4 adj. EPS 59c, consensus 55c »

As of December 31, 2018,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

AEP

American Electric

$77.00

0.65 (0.85%)

07:11
01/24/19
01/24
07:11
01/24/19
07:11
Earnings
Breaking Earnings news story on American Electric »

American Electric backs…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

AEP

American Electric

$77.00

0.65 (0.85%)

07:10
01/24/19
01/24
07:10
01/24/19
07:10
Earnings
American Electric reports Q4 EPS 74c, consensus 71c »

Reports Q4 revenue $3.8B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

LVS

Las Vegas Sands

$57.25

0.26 (0.46%)

07:10
01/24/19
01/24
07:10
01/24/19
07:10
Recommendations
Las Vegas Sands analyst commentary  »

Las Vegas Sands price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

CNCE

Concert Pharmaceuticals

$14.02

-0.26 (-1.82%)

07:10
01/24/19
01/24
07:10
01/24/19
07:10
Hot Stocks
Concert Pharmaceuticals initiates Phase 1 single-ascending dose trial of CTP-692 »

Concert Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

  • 30

    Jan

  • 12

    Feb

  • 13

    Feb

MDR

McDermott

$8.49

0.01 (0.12%)

07:09
01/24/19
01/24
07:09
01/24/19
07:09
Hot Stocks
McDermott announces ethylene furnace award in Indonesia »

McDermott announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

BWB

Bridgewater Bancshares

$10.41

-0.17 (-1.61%)

07:09
01/24/19
01/24
07:09
01/24/19
07:09
Earnings
Bridgewater Bancshares reports Q4 EPS 25c, two est. 23c »

The fourth quarter of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLDC

China Lending Corp.

$1.11

-0.005 (-0.45%)

07:09
01/24/19
01/24
07:09
01/24/19
07:09
Hot Stocks
China Lending Corp. acquires minority interest in financial service company »

China Lending Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

RCI

Rogers Communications

$54.51

-0.12 (-0.22%)

07:09
01/24/19
01/24
07:09
01/24/19
07:09
Earnings
Rogers Communications sees FY19 revenue up 3%-5% »

Sees FY19 adjusted EBITDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

LIVX

LiveXLive Media

$6.25

-0.05 (-0.79%)

07:08
01/24/19
01/24
07:08
01/24/19
07:08
Recommendations
LiveXLive Media analyst commentary  »

LiveXLive Media price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRIS

Curis

$1.06

-0.045 (-4.09%)

07:08
01/24/19
01/24
07:08
01/24/19
07:08
Hot Stocks
Curis says first mesothelioma patient dosed in CA-170 study »

Curis announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.